Physician profile
Roy Carlson
NPI 1932142858
$951.27
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $84.20 · 2021: $142 · 2022: $191 · 2023: $60.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $169.40 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $121.98 | 2019-2022 | |
| Optinose US, INC. | $110.51 | 2019-2021 | |
| Alk-Abello, INC | $97.25 | 2019-2020 | |
| Medtronic USA, INC. | $94.97 | 2019 | |
| Glaxosmithkline, LLC. | $59.66 | 2020-2022 | |
| Kaleo, INC. | $42.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.68 | 2022 | |
| Acclarent, INC | $31.30 | 2021-2022 | |
| Boston Scientific Corporation | $30.88 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Smith+Nephew, INC. | $26.59 | 2019 | |
| Medtronic, INC. | $24.31 | 2023 | Ligasure |
| Karl Storz Endoscopy-America | $23.34 | 2019 | |
| Aerin Medical INC. | $16.78 | 2019 | |
| Aimmune Therapeutics, INC. | $14.53 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.03 | 2021 | |
| Axogen | $12.73 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.45 | 2021 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.